endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

Deals channel feed

De­vel­op­ing a Sanofi cast-off, Im­pact Bio­med­i­cines now sub­ject of $7B Cel­gene ac­qui­si­tion deal

8 years ago

Af­ter re­sist­ing a push to the auc­tion block, Acor­da preps for a sale and shares shoot up — re­port

8 years ago

Take­da swoops in to buy stem cell part­ner TiGenix for $630M, putting it on the thresh­old of a like­ly ap­proval

8 years ago

SVB's crys­tal ball points to big mon­ey biotech IPOs, down­shift in the tor­rid pace of ven­ture in­vest­ing

8 years ago
Financing
Pharma

INC Re­search and in­Ven­tiv Health come un­der Sy­neos Health brand in clos­ing chap­ter of CRO merg­er

8 years ago
Outsourcing

On a deal spree, Mallinck­rodt bags Su­cam­po and two late-stage rare dis­ease drugs for $1.2B

8 years ago

Roche lines up at the FDA's 10-yard line with $1.7B Igny­ta buy­out

8 years ago

Af­ter ax­ing a top drug, Mil­len­do bags a PhII re­place­ment with biotech buy­out

8 years ago

Al­ler­gan buys an ail­ing Re­pros, bag­ging a women’s health drug for the pipeline

8 years ago
Pharma

M&A slows to a trick­le in 2017, but Big Phar­ma could be on deck for mega deals

8 years ago

Gilead swoops in with $567M deal to buy CAR-T 2.0 play­er Cell De­sign Labs

8 years ago

An­a­lysts’ top 10 biotech takeover tar­gets are con­cen­trat­ed in two key ar­eas

8 years ago
Special

Bio­phar­ma's top 10 over­seas cash hoards. And what kind of M&A spree would $171B buy?

8 years ago

Af­ter all the love and mon­ey, an­a­lysts spec­u­late that J&J may swoop in with a buy­out of­fer for Gen­mab

8 years ago
Pharma

Blue­bird bio or­ches­trates a se­ries of deals and a buy­out to guar­an­tee gene ther­a­py man­u­fac­tur­ing

8 years ago
Cell/Gene Tx

Say it with us: IQVIA is the new Quin­tiles and IMS Health

8 years ago
Outsourcing

Mallinck­rodt bags an­oth­er mi­cro­cap biotech, pick­ing up Ocera’s failed drug in $117M buy­out

8 years ago

Neos con­sid­er­ing of­fers af­ter re­ject­ing PDL’s $300M bid: Reuters

8 years ago

Vaxart re­verse merges its way on­to Nas­daq, climb­ing aboard the Avi­ra­gen shell

8 years ago

No­var­tis builds can­cer pipeline with a new plat­form/drug buy­out, bag­ging Ad­vanced Ac­cel­er­a­tor Ap­pli­ca­tions for $3.9B

8 years ago

In a switch, Mer­ck CEO sig­nals he’s in a deal-mak­ing frame of mind

8 years ago

PDL gets ag­gres­sive with an of­fer to buy out Neos Ther­a­peu­tics

8 years ago

Take­da part­ner Finch joins forces with Cresto­vo, leap­ing in­to a mid-stage mi­cro­bio­me study

8 years ago

Orex­i­gen posts a ‘for sale’ sign in the yard as weak Con­trave sales raise con­cerns

8 years ago
First page Previous page 110111112113114115116 Next page Last page
A service from the Financial Times